After repeated unsuccessful cancer treatments, even the strongest patients can lose hope. But former University of Virginia School of Medicine assistant professors Tomasz Cierpicki and Jolanta ...

UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...

CEO Richard Adcock used a presentation at the Citizens Life Sciences Conference to outline the company’s commercial progress ...

Joshua Abbott-Littler had only rang the bell at the Christie a year before to celebrate getting the "all clear" from his cancer diagnosis ...

Michelle Smith was told she had eczema as a teenager but her skin condition gradually worsened over years - until doctors discovered she actually had stage 4 peripheral T-cell lymphoma ...

High glyphosate use is linked to elevated rates of non-Hodgkin lymphoma cancer, particularly in Iowa and the Upper Midwest, finds a new Food & Water Watch analysis. Accompanying the analysis is a new ...

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after frontline therapy. Advances in chemotherapy, radiation techniques and targeted ...

The scientists have designed an approach that both targets the tumors’ molecular identity and counters the evasion strategy the cancer employs in response.

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

PARIS, FRANCE, 09 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.